+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Pharmaceutical Sector Report 2020 1st Quarter - Product Image

China Pharmaceutical Sector Report 2020 1st Quarter

  • ID: 5026438
  • Report
  • April 2020
  • Region: China
  • 62 pages
  • EMIS, An ISI Emerging Markets Group Company
This report provides a complete and detailed analysis of the pharmaceutical sector for China. The report presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:
  • Understand the key elements at play in the pharmaceutical sector in China
  • Access forecasts for growth in the sector
  • View key data on production and sales for the sector in China
  • Crystallise the forces both driving and restraining this sector in China
  • Build a complete perspective on sector trade, investment and employment
  • Understand the competitive landscape and who the major players are
  • View M&A activity and major deals
  • Gain an understanding of the regulatory environment for the sector in China
  • Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine)
Note: Product cover images may vary from those shown
01 EXECUTIVE SUMMARY
  • Sector in Numbers
  • Sector Overview
  • Sector Snapshot
  • Driving Forces
  • Restraining Forces
02 SECTOR IN FOCUS Quarterly Update
  • China Pharmaceutical Manufacturing 2019 Q4
  • Quarterly Summary
  • Sector Outlook
  • Sector Highlights
  • Main Sector Indicators
  • Top M&A Deals
  • M&A Activity
03 COMPETITIVE LANDSCAPE
  • Timeline China Pharmaceutical Sector
  • Highlights
  • Top Pharmaceutical Enterprises
04 COMPANIES IN FOCUS
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
  • China National Medicines Corporation Ltd
  • Shenzhen Neptunus Bioengineering Co Ltd
  • Nanjing Pharmaceutical Co Ltd
05 REGULATORY ENVIRONMENT
  • Government Policy
  • Healthy China 2030
  • Anti-Corruption Policies
06 CHEMICAL MEDICINES
  • Highlights
  • Main Events
  • Main Indicators
07 TRADITIONAL CHINESE MEDICINES
  • Highlights
  • Main Events
  • Main Indicators
Note: Product cover images may vary from those shown

Loading
LOADING...

In the fourth quarter of 2019, China’s production volume of active pharmaceutical ingredients (API) declined by 12.7% y/y to 633,000 tonnes, mainly due to the environment-driven production cuts. The decline in output dragged down the sales volume of API, which dropped by 15.9% y/y to 594,200 tonnes. China’s centralised drug procurement scheme launched at the end of 2018, resulted in a notable decline in drug prices. Many producers experienced significant profit drops and some even suffered financial losses. Furthermore, there was a high pressure to limit the output of some heavily polluting API plants due to environmental concerns, which also had a negative effect on API production. In Q4 2019, the production of TCM in China reached 609,000 tonnes, inching up by 0.2% y/y.
Note: Product cover images may vary from those shown
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
  • China National Medicines Corporation Ltd
  • Shenzhen Neptunus Bioengineering Co Ltd
  • Nanjing Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll